Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

EntreMed Sweetens Private Placement with China Rights to Cancer Drug

publication date: Sep 10, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
EntreMed raised $5.1 million in a private placement that featured an unusual sweetener for the investors: a 16-month option on the China marketing rights to EntreMed’s lead drug candidate. The funding placed 1,886,662 units at a price of $2.70 (EntreMed closed at $3.00), each unit consisting of 1 share of stock and a three-year warrant for .2 share – the upshot being that outside of the marketing option, the transaction was structured as a normal private placement.  More details....

Stock Symbol: (NSDQ: ENMD)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...